BRPI0920878A2 - inbidor de ksp161 para aumentar apoptose, sua administração e seu uso. - Google Patents

inbidor de ksp161 para aumentar apoptose, sua administração e seu uso.

Info

Publication number: BRPI0920878A2
Authority: BR; Brazil
Prior art keywords: ksp161; inhibitor; administration; increase apoptosis; apoptosis
Prior art date: 2008-10-16

Application number

BRPI0920878A

Other languages

English (en)

Inventor

Brian J Tunquist

Duncan H Walker

Richard Donald Woessner

Original Assignee

Array Biopharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-16

Filing date

2009-10-16

Publication date

2015-12-22

2009-10-16 Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc

2015-12-22 Publication of BRPI0920878A2 publication Critical patent/BRPI0920878A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Hematology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

BRPI0920878A 2008-10-16 2009-10-16 inbidor de ksp161 para aumentar apoptose, sua administração e seu uso. BRPI0920878A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10608608P	2008-10-16	2008-10-16
PCT/US2009/061106 WO2010045624A1 (en)	2008-10-16	2009-10-16	Inhibitors of mitosis for increasing apoptosis in therapy

Publications (1)

Publication Number	Publication Date
BRPI0920878A2 true BRPI0920878A2 (pt)	2015-12-22

Family

ID=41508147

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0920878A BRPI0920878A2 (pt)	2008-10-16	2009-10-16	inbidor de ksp161 para aumentar apoptose, sua administração e seu uso.

Country Status (19)

Country	Link
EP (1)	EP2349259B1 (pt)
JP (2)	JP5749170B2 (pt)
CN (2)	CN104958292B (pt)
AU (1)	AU2009305588B2 (pt)
BR (1)	BRPI0920878A2 (pt)
CA (1)	CA2741069C (pt)
CY (1)	CY1117281T1 (pt)
DK (1)	DK2349259T3 (pt)
ES (1)	ES2565778T3 (pt)
HR (1)	HRP20160267T1 (pt)
HU (1)	HUE027170T2 (pt)
IL (1)	IL212413A (pt)
PL (1)	PL2349259T3 (pt)
RS (1)	RS54647B1 (pt)
RU (1)	RU2519145C2 (pt)
SI (1)	SI2349259T1 (pt)
SM (1)	SMT201600073B (pt)
UA (1)	UA106214C2 (pt)
WO (1)	WO2010045624A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5749170B2 (ja) *	2008-10-16	2015-07-15	アレイバイオファーマ、インコーポレイテッド	治療におけるアポトーシスを増加させるための有糸分裂の阻害剤
TWI427054B (zh) *	2012-01-20	2014-02-21	Nat Univ Chung Hsing	A pharmaceutical composition for inhibiting and treating a lung tumor and inhibiting an inflammatory reaction and a method for preparing the same
KR20150042280A (ko) *	2012-08-13	2015-04-20	어레이 바이오파마 인크.	낮은 aag를 보유한 환자에서 암 치료 용도의 arry-520
AU2014227478A1 (en)	2013-08-08	2015-02-26	Array Biopharma Inc.	Filanesib combined with pomalidomide displays enhanced anti-tumor activity
WO2016127000A1 (en)	2015-02-04	2016-08-11	Bristol-Myers Squibb Company	Methods of selecting therapeutic molecules
JP7340240B2 (ja) *	2019-08-26	2023-09-07	学校法人関西医科大学	細胞又は組織にアポトーシスを誘導する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1641777A1 (de) *	2003-06-05	2006-04-05	Zentaris GmbH	Indolderivate mit apoptose induzierender wirkung
US7449486B2 (en) *	2004-10-19	2008-11-11	Array Biopharma Inc.	Mitotic kinesin inhibitors and methods of use thereof
JP5749170B2 (ja) *	2008-10-16	2015-07-15	アレイバイオファーマ、インコーポレイテッド	治療におけるアポトーシスを増加させるための有糸分裂の阻害剤

2009
- 2009-10-16 JP JP2011532305A patent/JP5749170B2/ja active Active
- 2009-10-16 PL PL09748884T patent/PL2349259T3/pl unknown
- 2009-10-16 HR HRP20160267TT patent/HRP20160267T1/hr unknown
- 2009-10-16 UA UAA201106118A patent/UA106214C2/ru unknown
- 2009-10-16 RS RS20160175A patent/RS54647B1/sr unknown
- 2009-10-16 DK DK09748884.5T patent/DK2349259T3/en active
- 2009-10-16 EP EP09748884.5A patent/EP2349259B1/en active Active
- 2009-10-16 BR BRPI0920878A patent/BRPI0920878A2/pt not_active IP Right Cessation
- 2009-10-16 HU HUE09748884A patent/HUE027170T2/hu unknown
- 2009-10-16 RU RU2011119427/15A patent/RU2519145C2/ru active
- 2009-10-16 CN CN201510222295.1A patent/CN104958292B/zh active Active
- 2009-10-16 WO PCT/US2009/061106 patent/WO2010045624A1/en not_active Ceased
- 2009-10-16 ES ES09748884.5T patent/ES2565778T3/es active Active
- 2009-10-16 CN CN200980150472.2A patent/CN102256603B/zh active Active
- 2009-10-16 AU AU2009305588A patent/AU2009305588B2/en active Active
- 2009-10-16 SI SI200931379T patent/SI2349259T1/sl unknown
- 2009-10-16 CA CA2741069A patent/CA2741069C/en active Active
2011
- 2011-04-17 IL IL212413A patent/IL212413A/en active IP Right Grant
2014
- 2014-05-19 JP JP2014102987A patent/JP2014144979A/ja active Pending
2016
- 2016-03-10 CY CY20161100206T patent/CY1117281T1/el unknown
- 2016-03-14 SM SM201600073T patent/SMT201600073B/xx unknown

Also Published As

Publication number	Publication date
EP2349259A1 (en)	2011-08-03
JP2012505924A (ja)	2012-03-08
SMT201600073B (it)	2016-04-29
ES2565778T3 (es)	2016-04-06
IL212413A0 (en)	2011-06-30
CA2741069A1 (en)	2010-04-22
EP2349259B1 (en)	2015-12-23
WO2010045624A1 (en)	2010-04-22
RU2519145C2 (ru)	2014-06-10
CN102256603A (zh)	2011-11-23
PL2349259T3 (pl)	2016-07-29
SI2349259T1 (sl)	2016-03-31
RU2011119427A (ru)	2012-11-27
AU2009305588A1 (en)	2010-04-22
JP2014144979A (ja)	2014-08-14
HK1154813A1 (zh)	2012-05-04
CY1117281T1 (el)	2017-04-26
CN104958292A (zh)	2015-10-07
AU2009305588B2 (en)	2015-08-13
JP5749170B2 (ja)	2015-07-15
UA106214C2 (ru)	2014-08-11
HUE027170T2 (hu)	2016-10-28
RS54647B1 (sr)	2016-08-31
HRP20160267T1 (hr)	2016-04-08
CN102256603B (zh)	2015-06-03
CN104958292B (zh)	2018-10-16
DK2349259T3 (en)	2016-02-29
CA2741069C (en)	2017-08-22
IL212413A (en)	2015-08-31

Publication	Publication Date	Title
BRPI0912356A2 (pt)	2015-10-06	compostos moduladores de sirtuína, composição farmacêutica compreendendo os mesmos e seu uso
BRPI1010621A2 (pt)	2016-06-21	derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso
BR112012004335A2 (pt)	2015-09-08	composto, composição farmacêutica, e, uso do composto.
BRPI1010768A2 (pt)	2016-11-01	composto, e, composição farmacêutica.
BRPI1007018A2 (pt)	2016-03-29	composto, composição farmacêutica, e , uso de um composto.
BRPI1008692A2 (pt)	2016-03-08	moléculas de anticorpos tendo especificidade para ox40 humano.
CL2008000403A1 (es)	2008-08-18	Compuestos derivados de pentafluorotiobenzamido-acetonitrilo; composicion farmaceutica; y uso para tratar una infestacion por parasitos.
BRPI1008906A2 (pt)	2016-03-15	composto, composição farmacêutica, e, uso de um composto.
BRPI0717638A2 (pt)	2013-11-12	Anticorpors e imunoconjugados e usos para os mesmos
HRP20160579T1 (hr)	2016-07-29	Spoj indola i njegova farmaceutska upotreba
BRPI0819188A2 (pt)	2015-09-01	Uso de melanocortinas para tratar sensibilidade à insulina.
CL2013000801A1 (es)	2013-11-29	Composicion farmaceutica que comprende un inhibidor de rankl y una hormona o un derivado de la misma, y uso del inhibidor rankl para preparar dicha composicion
BRPI0807907A2 (pt)	2017-05-16	co-cristais e composições farmacêuticas compreendendo os mesmos.
FR2936709B1 (fr)	2012-05-11	Comprimes alcoolo-resistants.
CL2007002552S1 (es)	2008-04-18	Pajilla para beber.
BRPI0818459A2 (pt)	2015-04-14	Composição farmacêutica adequada para uso oftálmico.
BRPI0915552A2 (pt)	2017-06-20	derivados de ciclosporina, seu uso e sua composição farmacêutica
BRPI0817542A2 (pt)	2014-10-07	NOVOS INIBIDORES DE sEH E SEU USO
BRPI1009757A2 (pt)	2016-03-15	composto, composição farmacêutica, e , uso de um composto.
CL2013001411A1 (es)	2014-03-28	Peptido que posee actividad antiapoptotica; conjugado que lo comprende; composicion farmaceutica que lo comprende; y su uso para tratar una enfermedad o condicion asociada con apoptosis en un sujeto.
EP2099789A4 (en)	2012-02-15	INHIBITORS OF HIV REPLICATION
EP2197448A4 (en)	2010-11-17	dosing schedule
BRPI0920878A2 (pt)	2015-12-22	inbidor de ksp161 para aumentar apoptose, sua administração e seu uso.
BRPI1014125A2 (pt)	2016-04-12	composto, composição farmacêutica, e, uso de um composto.
BRPI1013597A2 (pt)	2016-04-19	seringa para uso único

Legal Events

Date	Code	Title	Description
2018-04-17	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-24	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2020-03-10	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-03-17	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2020-08-18	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2020-11-24	B09B	Patent application refused [chapter 9.2 patent gazette]
2021-02-02	B12B	Appeal against refusal [chapter 12.2 patent gazette]
2025-09-16	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 16A ANUIDADE.
2026-01-06	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2854 DE 16-09-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.